{"entity":{"id":"nct07359820","kind":"trial","name":"A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement","aka":[],"tldr":"A phase 2 trial of Lirafugratinib in advanced solid tumours, run by Elevar Therapeutics, now recruiting.","summary":"A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement is a phase 2 interventional study registered as NCT07359820 by Elevar Therapeutics, with 30 participants planned, started 2026-06-04 and due to reach its primary completion in 2027-09. Interventions recorded: Lirafugratinib.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07359820","url":"https://clinicaltrials.gov/study/NCT07359820"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["lirafugratinib"],"companies":["elevar-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07359820","phase":"2","setting":"A Phase 2, Open-Label, Single-Arm Study of Lirafugratinib in Patients With Previously Treated, Unresectable, Locally Advanced or Metastatic Solid Tumors (Excluding Cholangiocarcinoma) With FGFR2 Fusion or Rearrangement","sponsor":"Elevar Therapeutics","enrolled":30,"outcomes":[]},"route":"/trials/nct07359820/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"lirafugratinib","kind":"drug","name":"Lirafugratinib","route":"/drugs/lirafugratinib/"}],"company":[{"id":"elevar-therapeutics","kind":"company","name":"Elevar Therapeutics (HLB)","route":"/companies/elevar-therapeutics/"}]}}